Analytical Data
-
基因名
CCL24
- Application
-
种属
Cynomolgus
-
表达系统
HEK293
-
标签
N-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
XP_005549400
-
表达区间
H19-H119
-
蛋白长度
Partial
-
分子量
23-38 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CCL24, also known as eotaxin-2, is a chemokine that plays a crucial role in the immune system, particularly in the recruitment of eosinophils and T-helper type 2 (Th2) cells to sites of inflammation. Elevated levels of CCL24 have been associated with various allergic and inflammatory diseases, such as asthma, allergic rhinitis, and atopic dermatitis, highlighting its potential as a therapeutic target. Research into the recombinant production of CCL24 protein has gained momentum, driven by the need for standardized reagents to study its functional mechanisms and interactions in human physiology. The development of CCL24 recombinant protein allows for more precise in vitro and in vivo investigations into its role in immune responses and disease pathology. Furthermore, understanding the signaling pathways mediated by CCL24 could provide insights into novel therapeutic strategies aimed at controlling eosinophilic inflammation and allergic reactions. The elucidation of CCL24's structural and functional properties is critical for the development of inhibitors or modulators that could effectively manipulate its activity in pathological conditions, ultimately contributing to improved treatment options for patients suffering from immune-mediated disorders. Thus, the research surrounding CCL24 recombinant protein not only enhances our understanding of chemokines in immune regulation but also holds significant promise for therapeutic advancements in treating related diseases.












